Jim Cramer on Recursion Pharmaceuticals: “It's a Let Down, Big Let Down” [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
invested in the stock, Cramer remarked, “That's, it's a let down, big let down. Came on the show, talked the big game, didn't deliver.” A stock market chart. Photo by Arturo A on Pexels Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotech company that uses automation, data science, and AI to accelerate drug discovery. The company develops treatments for genetic, infectious, and cancer-related diseases. During the December 4, 2025, episode's lightning round, a caller asked about the stock, and the Mad Money host replied: I'm telling you, I am myself confounded by it. The stock has been horrendous. We gotta put that right on the table. I'm talking about horrendous, okay? So I do not like to recommend horrendous stocks. It is so low that it comes in under the category of speculative. As long as you're willing to take the pain, they can't, you know, you said it, they have a lot of money, but wow, I have to tell you, bad taste in my mouth. Bad. While we acknowledge the potent
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Recent 1-Year Share Slump Accurately [Yahoo! Finance]Yahoo! Finance
- Recursion's First AI Clinical Proof Links Pipeline Progress With Valuation Gap [Yahoo! Finance]Yahoo! Finance
- What Makes Recursion Pharmaceuticals (RXRX) So Attractive [Yahoo! Finance]Yahoo! Finance
- Can This AI Stock Bounce Back in 2026? [Yahoo! Finance]Yahoo! Finance
- BoFA Lowers PT on Recursion Pharmaceuticals (RXRX), Keeps a Hold Rating [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 2/25/26 - Beat
RXRX
Sec Filings
- 3/17/26 - Form 144
- 3/11/26 - Form 4
- 3/11/26 - Form 4
- RXRX's page on the SEC website